BRPI0907028A2 - Métodos para tratamento de fibroides uterinos ou temores daí derivados, para reduzir ou interromper o sangramento em uma paciente afligida com fibroides uterinos, para prevenir ou tratar a anemia em uma paciente afligida com fibroides uterinos, para reduzir o tamanho dos fibroides uterinos, para reduzir o volume de uterinos, para prevenir a disseminação de fibroídes uterinos para outros órgãos em uma paciente afligida com fibroides uterinos e para o tratamento de leiomioma metastático - Google Patents

Métodos para tratamento de fibroides uterinos ou temores daí derivados, para reduzir ou interromper o sangramento em uma paciente afligida com fibroides uterinos, para prevenir ou tratar a anemia em uma paciente afligida com fibroides uterinos, para reduzir o tamanho dos fibroides uterinos, para reduzir o volume de uterinos, para prevenir a disseminação de fibroídes uterinos para outros órgãos em uma paciente afligida com fibroides uterinos e para o tratamento de leiomioma metastático

Info

Publication number
BRPI0907028A2
BRPI0907028A2 BRPI0907028-1A BRPI0907028A BRPI0907028A2 BR PI0907028 A2 BRPI0907028 A2 BR PI0907028A2 BR PI0907028 A BRPI0907028 A BR PI0907028A BR PI0907028 A2 BRPI0907028 A2 BR PI0907028A2
Authority
BR
Brazil
Prior art keywords
uterine fibroids
reduce
patient afflicted
uterine
prevent
Prior art date
Application number
BRPI0907028-1A
Other languages
English (en)
Inventor
Erin Gainer
Lynnette Nieman
André Ulmann
Diana Blithe
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907028(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of BRPI0907028A2 publication Critical patent/BRPI0907028A2/pt
Publication of BRPI0907028A8 publication Critical patent/BRPI0907028A8/pt
Publication of BRPI0907028B1 publication Critical patent/BRPI0907028B1/pt
Publication of BRPI0907028B8 publication Critical patent/BRPI0907028B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
BRPI0907028A 2008-01-29 2009-01-28 uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona BRPI0907028B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
US12/021,610 2008-01-29
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (4)

Publication Number Publication Date
BRPI0907028A2 true BRPI0907028A2 (pt) 2015-07-07
BRPI0907028A8 BRPI0907028A8 (pt) 2019-08-13
BRPI0907028B1 BRPI0907028B1 (pt) 2019-09-24
BRPI0907028B8 BRPI0907028B8 (pt) 2021-05-25

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907028A BRPI0907028B8 (pt) 2008-01-29 2009-01-28 uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona

Country Status (20)

Country Link
US (5) US8299050B2 (pt)
EP (2) EP2684565B1 (pt)
JP (2) JP5906016B2 (pt)
KR (2) KR20150055626A (pt)
AU (1) AU2009209652B2 (pt)
BR (1) BRPI0907028B8 (pt)
CA (2) CA2857798A1 (pt)
CY (1) CY1116485T1 (pt)
DK (1) DK2252301T3 (pt)
ES (1) ES2450592T3 (pt)
HR (1) HRP20140132T1 (pt)
IL (2) IL207182A (pt)
MX (1) MX2010008270A (pt)
NZ (1) NZ587439A (pt)
PL (1) PL2252301T3 (pt)
PT (1) PT2252301E (pt)
SI (1) SI2252301T1 (pt)
TW (1) TWI445537B (pt)
WO (1) WO2009095418A1 (pt)
ZA (1) ZA201006049B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
CN107260745A (zh) * 2010-03-22 2017-10-20 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
JP6200493B2 (ja) * 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
WO2014090976A1 (en) * 2012-12-14 2014-06-19 Laboratoire Hra-Pharma Copper intrauterine device
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
UY35528A (es) * 2013-04-10 2014-09-30 Preglem Sa Moduladores del receptor de la progesterona para uso en la terapia de fibromas uterinos
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
WO2016084070A1 (en) 2014-11-24 2016-06-02 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (pedf) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
WO2021166001A1 (en) 2020-02-19 2021-08-26 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
WO1996023503A1 (de) * 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6861415B2 (en) 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
BR9814136A (pt) * 1997-11-14 2000-10-03 Akzo Nobel Nv Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
JP2006519255A (ja) 2003-02-28 2006-08-24 アメリカ合衆国 １７α−アセトキシ−１１β−（４−Ｎ，Ｎ−ジメチルアミノフェニル）−１９−ノルプレグナ−４，９−ジエン−３，２０−ジオンの製造方法、その中間体及びそのような中間体の製造方法
EP1768625B1 (en) 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
CA2623678A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
TW200831110A (en) 2006-12-28 2008-08-01 Repros Therapeutics Inc Methods and formulations for improved bioavailability of antiprogestins
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
CA2857798A1 (en) 2009-09-06
AU2009209652B2 (en) 2013-03-21
US20130023506A1 (en) 2013-01-24
US20090192130A1 (en) 2009-07-30
US9682088B2 (en) 2017-06-20
BRPI0907028B1 (pt) 2019-09-24
CA2713254A1 (en) 2009-09-06
US9180133B2 (en) 2015-11-10
CA2713254C (en) 2014-10-07
TWI445537B (zh) 2014-07-21
JP2015120711A (ja) 2015-07-02
IL234149A0 (en) 2014-09-30
KR20110021709A (ko) 2011-03-04
BRPI0907028A8 (pt) 2019-08-13
JP5906016B2 (ja) 2016-04-20
EP2252301B1 (en) 2013-12-11
US8722653B2 (en) 2014-05-13
WO2009095418A1 (en) 2009-08-06
US20140187525A1 (en) 2014-07-03
IL207182A0 (en) 2010-12-30
ZA201006049B (en) 2011-05-25
PL2252301T3 (pl) 2014-07-31
JP2011510949A (ja) 2011-04-07
AU2009209652A1 (en) 2009-08-06
IL207182A (en) 2015-06-30
DK2252301T3 (en) 2014-02-17
JP6138838B2 (ja) 2017-05-31
BRPI0907028B8 (pt) 2021-05-25
IL234149B (en) 2019-02-28
ES2450592T3 (es) 2014-03-25
NZ587439A (en) 2012-06-29
MX2010008270A (es) 2011-01-14
EP2684565A1 (en) 2014-01-15
US8299050B2 (en) 2012-10-30
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
CY1116485T1 (el) 2017-03-15
US20170246189A1 (en) 2017-08-31
EP2684565B1 (en) 2019-10-02
HRP20140132T1 (hr) 2014-05-09
EP2252301A1 (en) 2010-11-24
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
TW200944211A (en) 2009-11-01
KR101571400B1 (ko) 2015-11-24

Similar Documents

Publication Publication Date Title
BRPI0907028A2 (pt) Métodos para tratamento de fibroides uterinos ou temores daí derivados, para reduzir ou interromper o sangramento em uma paciente afligida com fibroides uterinos, para prevenir ou tratar a anemia em uma paciente afligida com fibroides uterinos, para reduzir o tamanho dos fibroides uterinos, para reduzir o volume de uterinos, para prevenir a disseminação de fibroídes uterinos para outros órgãos em uma paciente afligida com fibroides uterinos e para o tratamento de leiomioma metastático
CY2019002I1 (el) Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας
CY2020043I2 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
HRP20160689T1 (hr) Selektivni modulatori progesterona za tretman uterinog krvarenja
DOP2007000069A (es) Agonistas del receptor gpr119 en métodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa ósea baja y la terapia combinada relacionada a estos agonistas
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0817741A2 (pt) Composição para tratamento de tecidos, e, processo de lavagem para deposição de partículas pró-bióticas em tecidos
BRPI0915986A2 (pt) composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BRPI0906527A2 (pt) aparelho para aplicação de bandagens em ferimentos e bandagem médica
EP2076313A4 (en) PREDETERMINED CONDUCTIVITY GELS FOR IRREVERSIBLE ELECTROPORATION OF FABRICS
PL2601961T3 (pl) Kompozycje zawierające LAG-3 i terapeutyczne przeciwciała oraz ich zastosowania w leczeniu raka
IL209738B (en) A combination of cannabidiol and tetrahydrocannabidiol (thc) for use in the treatment of glioblastoma
BRPI0912583A2 (pt) agregação de conteúdo tridimensional construído em dispositivos
BRPI0913189A2 (pt) dispositivo de injeção para cargas de aumento de tecido mole, agentes bioativos e outros materiais biocompatíveis em forma líquida ou gel
BR112012018969A2 (pt) disposição eletrocirúrgica instrumento eletricirurgico para utilização numa disposição eletrocirurgica e unidade de tratamento de uma disposição eletricirurgica
BRPI0917189A2 (pt) dispositivo para uso em tratamento cirúrgico de tórax em funil e método de tratamento.
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
GB0512073D0 (en) Device for use in treatment of varicose veins
DE112006003722A5 (de) Simulationssystem für chirurgische Eingriffe in der Human- und Veterinärmedizin
BRPI0916043A2 (pt) composição farmacêutica e alimento funcional para prevenir ou tratar câncer
DK2170877T5 (da) Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering
SG11201406032TA (en) Prophylactic or therapeutic agent for giant cell tumors occuring in bone and soft tissue or for chondrosarcoma
BRPI1006972A2 (pt) "dispositivo e instrumentação para facilitar a colocação de parafusos nos tecidos ósseos"
BRPI0817045A2 (pt) Tratamento de condições estrogênio-dependentes em mulheres pré-menopáusicas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RICHTER GEDEON NYRT. (HU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF